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It is now well established that chronic inflammation is a prominent feature of several neurodegenerative disorders
including Parkinson’s disease (PD). Growing evidence indicates that neuroinflammation can contribute greatly to
dopaminergic neuron degeneration and progression of the disease. Recent literature highlights that leucine-rich
repeat kinase 2 (LRRK2), a kinase mutated in both autosomal-dominantly inherited and sporadic PD cases, modulates
inflammation in response to different pathological stimuli. In this review, we outline the state of the art of LRRK2
functions in microglia cells and in neuroinflammation. Furthermore, we discuss the potential role of LRRK2 in
cytoskeleton remodeling and vesicle trafficking in microglia cells under physiological and pathological conditions. We
also hypothesize that LRRK2 mutations might sensitize microglia cells toward a pro-inflammatory state, which in turn
results in exacerbated inflammation with consequent neurodegeneration.
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Leucine-rich repeat kinase 2 (LRRK2) is a large multido-
main protein belonging to the family of mammalian
ROCO (Ras Of COmplex) proteins, and characterized by
the presence of an enzymatic core, comprising ROC/
GTPase, COR (C-terminus of ROC) and serine threonine
kinase domains, and by multiple protein-protein inter-
action domains including ankyrin and leucine-rich repeat
motifs at the N-terminus, and WD40 repeats at the C-
terminus [1,2]. Although the physiological functions of
LRRK2 are still unclear, the presence of both a GTPase
and a kinase domain suggest a role in intracellular signal-
ing, and the existence of different protein binding domains
points to an additional function as a scaffolding protein for
the assembly of protein complexes [3].
Mutations in LRRK2 cause autosomal-dominantly
inherited Parkinson’s Disease, while more common varia-
tions can also act as risk factors for disease, accounting for
13% of all familial PD cases, and 1 to 2% of all sporadic
PD cases [1,4,5]. Despite intensive research efforts, little is
known about the pathogenic mechanism(s) of mutant
LRRK2. Interestingly, LRRK2-associated PD is clinically
and pathologically similar to sporadic PD, thus indicating* Correspondence: isabella.russo@unipd.it; elisa.greggio@unipd.it
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Several mutations in LRRK2 clearly segregate with the dis-
ease, and, importantly, these mutations cluster within the
two catalytic domains, suggesting that a change in enzym-
atic functions (GTPase and/or kinase) may mediate the
pathogenic effects of LRRK2 [6]. R1441G/C/H mutations
map to the ROC domain [4,7,8], Y1669C to the COR do-
main [1], and I2020T and G2019S mutations to the kinase
domain [9,10]. In this frame, the G2019S mutation is by
far the most common pathogenic LRRK2 mutation, and is
responsible for more than 10% of familial PD cases and 1
to 2% of sporadic PD cases [11]. Several studies have
shown that of all the LRRK2 mutations, only the G2019S
mutation consistently increases kinase activity [12-14].
Specifically, in vitro phosphorylation assays from independ-
ent studies showed an approximately three fold increase
in kinase activity in comparison with wild-type protein,
whereas ROC-COR mutations display inconsistent effects
on kinase, but have significantly lower GTPase activity
[15-18]. Conversely, the effect of the I2020T mutation on
kinase activity is less clear, with studies observing both in-
creased [19] and decreased [20,21] activity. However, the
effects of LRRK2 mutations on kinase activity have been
mainly examined in vitro by monitoring autophosphoryl-
ation or phosphorylation of model peptides, making it diffi-
cult to understand the real effects of mutations on LRRK2td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Russo et al. Journal of Neuroinflammation 2014, 11:52 Page 2 of 9
http://www.jneuroinflammation.com/content/11/1/52physiological functions. Interestingly, a recent paper by
Sheng and colleagues reported that autophosphorylation on
serine 1292 is a direct indicator of LRRK2 kinase activity
in vivo, and that additional mutations, other than G2019S,
appear to increase autophosphorylation at this site [22],
consistent with an in vitro study focused on autophospho-
rylation [23]. Monitoring phosphorylation of serine 1292 in
cells represents an important tool for future studies ad-
dressing pathways and signaling networks that relate to
LRRK2 kinase function.
In the brain, LRRK2, both mRNA and protein, has been
detected in specific regions including the cortex, striatum,
hippocampus, and with substantial lower expression, in the
substantia nigra pars compacta (SNpc) [24-26]. LRRK2 has
been reported to localize within a wide range of vesicular
and membranous structures, such as mitochondria, endo-
plasmic reticulum, and Golgi apparatus, as well as the
endolysosomal system and synaptic vesicles [25,27-29]. Al-
though LRRK2 protein is expressed in various brain cell
types such as neurons, microglia, and astrocytes [30], the
vast majority of studies to date have focused on investigat-
ing LRRK2 functions in neurons, being the relevant cell
type that degenerates in PD. The physiological functions of
LRRK2 in neuronal cells have been linked to vesicular traf-
ficking [31,32], cytoskeletal dynamics [33,34], mitochon-
drial function [35,36], apoptosis [37], and regulation of the
autophagy pathway [38-41]; however, how LRRK2 muta-
tions cause neurodegeneration in PD is currently under
debate.Effects of reactive microglia and neuroinflammation in
the pathogenesis of PD
It is now well established that chronic inflammation is a
prominent feature of several neurodegenerative disorders,
including PD [42,43]. The inflammatory response is driven
by the activation of resident macrophages, local invasion
of circulating immune cells, and production of cytokines,
chemokines, and reactive oxygen species, all essential to
recruit cells of the immune system to the compromised
area [42]. Microglia cells, the resident macrophages of the
brain, constitute the first barrier of the innate immune re-
sponse in the brain, and are considered to be key players
during neuroinflammation [42,44,45]. Microglia cells con-
tinually survey the microenvironment, and upon detection
of abnormal changes in the surrounding tissue, they rap-
idly become activated, secrete inflammatory mediators,
and migrate to the damaged area to eliminate pathogens
or to phagocyte dead cells and/or aggregated proteins
[46,47]. Although a well-regulated inflammatory process is
essential for tissue repair and CNS integrity, an excessive
and protracted inflammatory response can turn cytotoxic,
leading to significant tissue and cellular damage, thus pro-
moting the progression of the disease [42,48].It has been widely reported that chronic inflammation
can contribute to the degeneration of dopaminergic neu-
rons and to the progression of PD [48,49]. Elevated levels
of pro-inflammatory cytokines (tumour necrosis factor
(TNF)-α, interferon (IFN)-γ, interleukin (IL)-1β, and IL-6)
have been found in the cerebrospinal fluid, striatum and
SNpc of experimental animal models and of post-mortem
brains from patients with PD [48-50]. Moreover, the pres-
ence of extensive proliferation of reactive and phagocytic
macrophages positive for human leukocyte antigen (HLA)
has been shown around dopaminergic neurons in the SNpc
of patients with PD [51], in animal models, and in patients
with parkinsonism after 1-methyl-4-phenyl-1,2,3,6-tetrahy-
dropyridine (MPTP) exposure [52,53], further indicating
that microglia cells and their mediators might lead to neur-
onal damage and degeneration [54,55].
Microglia-mediated dopaminergic neurodegeneration is
supported by numerous studies. In fact, this class of neu-
rons exhibits a reduced antioxidant capacity and enhanced
sensitivity to pro-inflammatory mediators, probably as a
result of the high density of microglia cells present in
SNpc compared to other brain regions [56-59]. Ouchi and
colleagues reported that microglia activation in the mid-
brain is positively correlated with dopaminergic neuronal
death and motor symptom severity in the early stage of
PD [60], supporting the notion that reactive microglia ex-
acerbate the progression of the disease.
Supporting evidence for a direct role of inflammation
in PD has recently emerged from genome-wide associ-
ation studies (GWAS). Specifically, polymorphisms in
genes encoding inflammatory cytokines such as TNF-α
and IL-1β, and cell-surface human leukocyte antigen
(HLA) are associated with a higher risk of developing PD
[61-64]. These genes are predominantly expressed in glial
cells, and are directly involved in the inflammatory process
[65]. Although it is still controversial whether inflamma-
tion is causative or a secondary effect of earlier patho-
logical events of PD, there is an increasing recognition of
neuroinflammation as a major player in the pathology of
this disease.
Remarkably, LRRK2 has been identified by GWAS as
one of the susceptibility genes for leprosy and possibly for
Crohn’s disease [66-68], two illnesses with a strong inflam-
matory component. Based on these genetic findings, a
number of recent studies have explored the putative role
of LRRK2 in microglia cells and the impact of LRRK2 mu-
tations in the inflammatory response associated with PD.
What is the role of LRRK2 in microglia cells?
Microglia are highly dynamic cells with vastly branched
and motile cell processes, which constantly screen the brain
parenchyma, ready to detect any changes in the tissue [47].
In response to pathological stimuli such as lipopolysacchar-
ide (LPS), aggregated proteins, or dead neurons, microglia
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ameboid, activated phenotype [47,69,70]. Once they have
migrated toward a damaged area, they initiate a repairing
program through the release of inflammatory mediators
and the removal of debris by phagocytosis [71]. A number
of LRRK2 pathways have been described in neuronal cells
[72-74], but here we will discuss the potential roles of this
protein in the physiological and pathological functions of
microglia cells.
Immune-related cellular pathways
Recent findings indicate elevated LRRK2 mRNA and pro-
tein expression in immune cells, particularly in microglia
and astrocytes from human and rodent brain [30,75,76],
and in peripheral blood mononuclear cells, mainly in B
cells, dendritic cells, and macrophages [77,78]. Giesert
et al. investigated potential LRRK2 mRNA splice variants
in brain cells [26]; they observed that both neurons and
astrocytes (but not microglia) express a transcript variant
containing the alternative exon 42a, which results in a pre-
mature stop codon and a predicted protein of 2152 amino
acids long. This finding is intriguing, as it suggests that
LRRK2 function(s) in microglia cells may be at least partly
different from those exerted in other brain cell types.
Interestingly, Moehle and colleagues observed a robust
induction of LRRK2 protein in microglia cells of mouse
SNpc or striatum after LPS-induced inflammation [30].
Furthermore, in vitro studies reported increased LRRK2
protein expression in microglia cell cultures after an in-
flammatory stimulus induced by LPS or IFN-γ [79], but
not after HIV-1 Tat protein-induced inflammation [76]. In
addition to increased expression levels, LRRK2 immuno-
precipitated from LPS-inflamed brains was more active in
in vitro autophosphorylation assays [30], possibly indicat-
ing that the protein is switched into an active conform-
ation. Although the exact mechanism is not clear, two
different studies reported that HIV-1 Tat protein-induced
inflammation of BV2 cells or Toll-like receptor (TLR) ago-
nists (but not TNF-α treatment of RAW264.7 macro-
phages) induced marked phosphorylation of LRRK2 at
serines 910 and 935 [76,80], a state that is possibly associ-
ated with an active LRRK2 form. Taken together, these
data suggest that LRRK2 expression and enzymatic activity
are required during an inflammatory response; however,
the specific pathways and signaling cascades that LRRK2
orchestrates have not been characterized.
Additional studies further support a role for LRRK2 as
regulator of inflammation. Murine microglia cells with
inhibited or down-regulated LRRK2 showed attenuated
levels of LPS-induced inflammatory mediators at the
mRNA and protein level, including TNF-α, IL-1β, IL-6
and inducible nitric oxide synthase (iNOS) [30,81]. In
particular, LRRK2 knockdown microglia exhibited a sig-
nificant reduction of nuclear factor kappa B (NF-κB)transcriptional activity following TLR-mediated immune
signaling induced by LPS, and an increase of DNA-binding
activity of the NF-κB p50 inhibitor subunit [81]. As NF-κB
activity is essential for induction of pro-inflammatory cyto-
kines [82-84], LRRK2 might control its activation and the
consequent transcription of pro-inflammatory mediators,
through a yet undisclosed mechanism. In another study,
Liu and colleagues demonstrated that LRRK2 can function
as negative regulator of nuclear factor of activated T cells
(NFAT) transcription factors, a class of molecules impli-
cated in the inflammatory response in a large set of im-
mune cells [85]. In particular, they observed that LRRK2
inhibits NFAT nuclear translocation in a TLR-independent
manner, and thus inhibits the transcription of immune re-
sponse genes via interaction with the NRON (noncoding
(RNA) repressor of NFAT) complex in immune peripheral
cells [62]. Although a significant amount of progress has
been made, how LRRK2 modulates transcription factors
and induction of inflammatory genes remains controversial
and needs to be carefully explored.
Notably, Gillardon and colleagues [79] observed that
LPS-activated microglia cells from LRRK2 R1441G knock-
in mice exhibited increased expression and secretion of
pro-inflammatory cytokines and reduced expression of
anti-inflammatory cytokines compared with wild-type con-
trol microglia cells. Interestingly, gene expression profiling
of LRRK2 R1441G microglia cells under unstimulated con-
ditions revealed that several cytokines, chemokines, and
membrane receptors regulating microglia activation were
significantly increased compared with wild-type cells, indi-
cative of a basal sensitization toward a pro-inflammatory
phenotype. In addition, conditioned medium from LPS-
stimulated LRRK2 R1441G microglia added to primary
cortical neurons caused increased neuronal death com-
pared with medium from wild-type LRRK2 microglia.
Overall, these data indicate that LRRK2 is involved in the
cellular pathways induced by inflammation, and that
LRRK2 R1441G mutation might push microglia toward a
pro-inflammatory state, which results, in turn, in exacer-
bated inflammation and consequent neurodegeneration in
patients with PD (Figure 1).
Of note, Lopez de Maturana and colleagues recently re-
ported the effects of pro-inflammatory LPS stimulus on
epidermal cells from patients with PD who carried
R1441G or G2019S LRRK2 mutations, and patients with
idiopathic PD compared with controls [86]. Interestingly,
these authors found that patient cells had a blunted re-
sponse to LPS compared with control cells. However,
whether immune cells respond to LPS priming in a similar
manner remains to be determined.
Cytoskeleton reorganization
LRRK2 has been suggested to influence actin cytoskel-
eton and microtubule dynamics, and these functions
Figure 1 Abnormal activity of or mutations LRRK2 might push microglia cells toward a pro-inflammatory phenotype. Abnormal LRRK2
activity might modulate microglia cell activation and phagocytosis through hyperphosphorylation and hyperpolymerization of cytoskeleton
components such as actin and β-tubulin. Moreover, LRRK2 might regulate the delivery of membrane receptors (CD11b and MHC- II) and inflammatory
cytokines through regulation of transcription factors (such as NF-κB), and interaction and phoshorylation of vesicle-associated proteins such as Rab
GTPase and NSF, thus driving microglia toward a reactive phenotype with enhanced cell activity and inflammation in response to inflammatory stimuli
including LPS, environmental insults, and neuronal susceptibility.
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PD [73,87-89]. Various studies have reported the involve-
ment of LRRK2 kinase activity in neurite outgrowth and
maintenance of neuronal processes. There seems to be gen-
eral agreement that the LRRK2 G2019S mutation has
an inhibitory effect on neurite outgrowth and branching
[20,90-92]. In this context, Parisiadou and colleagues hy-
pothesized that the G2019S mutation causes increased
actin polymerization and ERM (ezrin, radixin, moesin) pro-
tein phosphorylation in neuronal filopodia, thus acting as a
physical barrier that prevents the extensions of microtubule
and leads, in turn, to inhibition of neuronal processes [73].
These observations find a link with the proposed function
of LRRK2 in the context of the microtubule network. In
particular, it was reported that LRRK2 interacts through its
ROC/GTPase domain and phosphorylates neuronal β-
tubulin both in vitro and in vivo, as demonstrated by re-
duced phosphorylation of β-tubulin immunoprecipitated
from knockout compared with wild-type mouse brains
[34,89,93]. Furthermore, in vitro LRRK2 enhances tubulin
polymerization in the presence of microtubule-associated
proteins [89,94], and phosphorylates tubulin-associated Tau
[95], whereas in vivo, Tau is hyperphosphorylated in brains
from R1441G trangenic mice [96]. Taken together, these
data indicate that LRRK2 regulates the organization of the
actin cytoskeleton and microtubule assembly.Cytoskeleton reorganization is also a critical step for
brain macrophage functions. Indeed, the rapid changes in
cell morphology and cell activity that microglia cells under-
take upon activation are governed by microtubules and by
actin cytoskeleton remodeling [87,97-99]. Even microglia
motility is a process that results from coordinated changes
in the actin cytoskeleton and in the formation of cell-
substrate adhesion sites. The actin cytoskeleton provides
the driving force at the cell front, while the microtubule
network regulates the rear retraction [97,99]. During mi-
gration, microglia cells exhibit long, thin extensions called
filopodia, which are supported by tight and dynamic bun-
dles of actin filaments that continuously polymerize and
depolymerize to support the cell movement [97,100-104].
Supporting a role of LRRK2 in cytoskeleton reor-
ganization during microglia activation, two recent studies
reported that inflammatory stimuli failed to induce signifi-
cant morphological changes of fine process extensions and
cytoskeleton remodeling in LRRK2 knockdown or LRRK2
inhibitor-treated microglia cells [30,76]. Moreover, Moehle
and colleagues observed in vitro that LRRK2 inhibition pre-
vents microglial migration in response to ADP, a potent
microglial chemoattractant [30]. Another study demon-
strated that human LRRK2 G2019S and mouse LRRK2
knockout fibroblasts exhibit altered cell migration in cul-
ture, with LRRK2 G2019S fibroblasts migrating faster and
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cells [87]. As the G2019S mutation increases LRRK2 cata-
lytic function, LRRK2 kinase activity appears to be required
for cytoskeleton remodeling and for motility of microglia
cells.
Microglia are the predominant phagocytes in the brain.
They act as a surveillance system for microbes and patho-
logical proteins, and remove apoptotic cells and cellular
debris in the brain [70]. They engulf and digest microbes or
pathological proteins by binding to them via specialized
surface receptors (such as TLRs) and subsequently trapping
them into a phagosome, which then fuses with a lysosome
to be digested [46,105]. Phagocytosis induces dramatic
changes in the shape and the movement of a cell, including
extension of the membrane and actin filaments, through
reorganization of the cytoskeleton [106]. Barcia and col-
leagues demonstrated using in vivo high-resolution imaging
that the entire microglia cell body is involved in the forma-
tion of a phagocytic cup [107]. Moreover, imaging of fluor-
escent actin molecules during phagocytosis showed
coordinated movement of the cytoskeleton in the cup,
which is mediated by a combination of localized actin
polymerization and depolymerization, together with the
contraction of actin filament networks [108]. Interestingly,
Marker et al. showed that LRRK2 might be involved in
microglia phagocytosis. They found that pharmacological
inhibition of LRRK2 attenuated microglial phagocytosis
of fluorescent beads after an inflammatory stimulus. In
addition, BV2-immortalized microglia cells co-cultured in
the axonal compartment of primary neurons (to study
phagocytosis of neuronal processes in the absence of cell
bodies), and exposed to inflammatory conditions, com-
pletely phagocytosed and destroyed axonal arbors. By con-
trast, treatment of co-cultures with the LRRK2 inibitor
IN-1 protected the axons and neuronal phagocytosis by
clearing microglia [76].
Overall, these data suggest that LRRK2 regulates micro-
glia activation, migration, and phagocytosis, although the
molecular mechanisms underlying these processes are still
unknown. One possibility is that LRRK2 orchestrates cyto-
skeletal components such as actin, tubulin. and ERM pro-
teins, and that the pathological G2019S mutation causes
hyperphosphorylation and hyperpolymerization of cytoskel-
eton components, which leads, in turn, to reactive micro-
glia with enhanced cell activity, migration, and phagocytosis
in response to pathological stimuli, thus contributing to the
pathogenesis of PD (Figure 1).
Vesicle trafficking
Strong evidence supports a role for LRRK2 in the secretory
and endocytic pathways. Multiple in vivo and in vitro stud-
ies have reported that LRRK2 overexpression or knock-
down affects synaptic vesicle endocytosis and exocytosis
[32,109,110]. In detail, LRRK2 modulates synaptic vesicletrafficking by interaction with pre-synaptic proteins such
as actin, syntaxin, synaptic vesicle glycoprotein 2A (SV2A),
N-ethylmaleimide-sensitive factor (NSF), and Synapsin I
[31]; affects synaptic vesicles endocytosis through inter-
action with Rab5b and EndoA, critical components of the
endocytic machinery [32,110]; and regulates the numbers
of readily releasable vesicles and their release in hippocam-
pal neurons by interaction and phosphorylation of Snapin
protein [111]. Importantly, the G2019S and R1441G muta-
tions were shown to increase the levels of dopamine recep-
tor D1 on the membrane surface [112], supporting the
notion that pathological LRRK2 activity might affect vesicle
trafficking and release.
LRRK2 has also been reported to regulate the endocytic
pathway involved in the autophagic-lysosomal process, an
important clearance route for several aggregated or un-
folded proteins. Interestingly, the LRRK2 Drosophila homo-
log interacts with Rab7, modulating the degradation of
autophagosomes [27]. Human LRRK2 forms a complex
with Rab7L1, an important component of the autophagic-
lysosomal pathway [113]. In addition, LRRK2 interacting
with Rab5 might also affect the early step of autophago-
some formation [114].
Vesicle trafficking in secretory and endocytic pathways
are well described in microglia cells during cytokine release,
delivery of membrane receptors to the cell membrane, and
phagocytosis [115,116]. Transport of inflammation-induced
cytokines (such as TNF-α and IL-6) from the endoplasmic
reticulum to the cell surface occurs through the endosomal
system, and relies on a complex array of trafficking machin-
ery to ensure the accurate docking and fusion of carrier
vesicles to their designated target membranes [117]. Deliv-
ery and internalization of membrane receptors in macro-
phages are essential for the regulation of cell activation
[118], and their trafficking also occurs through endo-
somes. Notably, Rab7 is fundamental for the trafficking of
receptor-containing vesicles involved in the inflammatory
response [119], thus supporting the notion that LRRK2
might affect the expression of membrane receptors on
microglia cells.
The endosomal pathway also plays a central role during
phagocytosis. Macrophages, when in contact with patho-
gens or dying cells, initiate a sequence of membrane fusion
events that culminate with the formation of a phagocytic
cup, which is followed by the formation of a nascent
phagosome around the ingested material, and its conse-
quent internalization [120]. The phagosome is then
reshaped to form the phagolysosome, where pathogens are
degraded to produce antigenic peptides. Multiple soluble
N-ethylmaleimide-sensitive factor attachment protein re-
ceptor (SNARE) proteins are required for the formation
and the maturation of phagosome. Specifically, phagocytic
cup formation is determined by fusion of the plasma mem-
brane with intracellular organelles including recycling
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which have a large amount of membrane and contain the
appropriate SNARE and Rab GTPase proteins. It has been
demonstrated that macrophages, when activated, regulate
the expression of SNAREs and GTPases to provide a large
set of proteins for membrane fusion, important for phago-
cytic cup formation [115].
Although a role for LRRK2 in vesicle trafficking in
microglia cells has not been described, we speculate that
LRRK2 activity may be important for the release of inflam-
matory mediators, delivery of membrane receptors, and
phagocytotic processes. In particular, LRRK2 might regu-
late the components of the fusion machinery, such as its
partner NSF [31] or Rab GTPase proteins, which have
been shown to contribute to the fusion of vesicles contain-
ing inflammatory mediators, receptors, and pathogens to
be eliminated. It should be noted that several receptors
regulating microglial activation, such as major histocom-
patibility complex (MHC) class II and CD11b, which have
also been observed to be up-regulated in brains of patients
with PD [51,121,122], showed increased mRNA expres-
sion under basal conditions in transgenic microglia with
LRRK2 R1441G mutation, thus suggesting that LRRK2
might affect the expression of these receptors. Moreover,
when these cells were activated with LPS, the levels of cy-
tokines/chemokines, proteins, and mRNAs massively in-
creased compared with wild-type cultures [79], thus
indicating that LRRK2 might play a key role in vesicle traf-
ficking and release in microglia cells and might be import-
ant in switching these cells toward a pro-inflammatory
phenotype (Figure 1).
Conclusions
Recent literature indicates that microglial LRRK2 plays a
role in the cellular pathways induced by inflammatory
stimuli. Based on its complex architecture with different
functional domains, LRRK2 might be involved in more
than one cellular process. Although a number of studies
have analyzed the effects of LRRK2 kinase activity using
different microglia-related readouts, such as morphological
changes and inflammatory mediator release, evidence on
how LRRK2 might affect these processes is currently lack-
ing. Here we hypothesize that abnormal LRRK2 kinase ac-
tivity, due to the presence of LRRK2 mutations, might
modulate the phenotype of microglia through hyperpoly-
merization and hyperphosphorylation of cytoskeleton and
vesicle components, thus pushing these cells toward a pro-
inflammatory state. In this regard, Gillardon and colleagues
observed that the LRRK2 R1441G mutation sensitizes
microglia cells toward a neurotoxic state [79]. Similar to
G2019S, the R1441G mutation causes an approximately
2.5-fold increase of serine 1292 autophosphorylation in
cells overexpressing LRRK2-R1441G compared with wild-
type LRRK2 [22], supporting the notion that the increasedkinase activity of LRRK2 may push microglia toward a pro-
inflammatory phenotype. One possibility is that the
R1441G mutation increases kinase activity through its re-
duced GTP hydrolysis activity, although the cross-talk be-
tween GTPase and the kinase domain is currently unclear
[12,21,123].
The identification of microglia-specific kinase substrates,
GTPase downstream effectors, and interactors, will pro-
vide valuable insight into the emerging function of LRRK2
in the regulation of neuroinflammation, with the potential
of uncovering new molecular mechanisms underlying the
pathogenesis of PD, and consequently novel targets for
drug treatments.
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